These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1378 related items for PubMed ID: 28610832
1. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Alatoom A, Elsayed H, Lawlor K, AbdelWareth L, El-Lababidi R, Cardona L, Mooty M, Bonilla MF, Nusair A, Mirza I. Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832 [Abstract] [Full Text] [Related]
8. Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases from U.S. Hospitals. Castanheira M, Doyle TB, Mendes RE, Sader HS. Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31085510 [Abstract] [Full Text] [Related]
9. Assessment of the In Vitro Activities of Ceftolozane/Tazobactam and Ceftazidime/Avibactam in a Collection of Beta-Lactam-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Clinical Isolates at Montpellier University Hospital, France. Viala B, Zaidi FZ, Bastide M, Dumont Y, Le Moing V, Jean-Pierre H, Godreuil S. Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764 [Abstract] [Full Text] [Related]
10. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates. Humphries RM, Hindler JA, Wong-Beringer A, Miller SA. Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338 [Abstract] [Full Text] [Related]
13. ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime. Jacobs MR, Abdelhamed AM, Good CE, Mack AR, Bethel CR, Marshall S, Hujer AM, Hujer KM, Patel R, van Duin D, Fowler VG, Rhoads DD, Six DA, Moeck G, Uehara T, Papp-Wallace KM, Bonomo RA. Antimicrob Agents Chemother; 2024 Sep 04; 68(9):e0075124. PubMed ID: 39133021 [Abstract] [Full Text] [Related]
14. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015). Pfaller MA, Shortridge D, Sader HS, Castanheira M, Flamm RK. Int J Antimicrob Agents; 2018 Feb 04; 51(2):181-189. PubMed ID: 28993143 [Abstract] [Full Text] [Related]
15. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States Medical Centers in 2016-2018. Sader HS, Carvalhaes CG, Streit JM, Doyle TB, Castanheira M. Microb Drug Resist; 2021 Mar 04; 27(3):342-349. PubMed ID: 32762605 [Abstract] [Full Text] [Related]